*GNLB (Fav's) news; new mgmt. talent, "Genelabs Introduces Management Team Members"
REDWOOD CITY, Calif., Aug. 24 /PRNewswire/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB - news) today introduced two members of its management team: Lynn M. Hughes, Vice President of Human Resources, and Ming S. Chen, Ph.D., Vice President of Research.
(Photo: newscom.com )
Ms. Hughes joined Genelabs from COR Therapeutics, where she was Director of Human Resources. During her four years at COR she was responsible for building COR's sales force for the commercial introduction of its first pharmaceutical product, INTEGRILIN®. Previously, Ms. Hughes held human resources positions with Navigation Technologies, Sony Electronics and Silicon Graphics.
Dr. Chen was Director of Biochemistry and Virology at Gilead Sciences, leading the department that discovered the anti-influenza activity of Tamiflu(TM), an oral treatment for influenza introduced to the United States market last year by Gilead Sciences and Hoffmann-LaRoche. Prior to joining Gilead, Dr. Chen held senior research positions with Syntex Research. His career has been focused on developing compounds through the FDA regulatory process. Dr. Chen has broad-ranging experience in many therapeutic areas, leading teams in drug discovery for cancer, viral infection, and autoimmune and infectious diseases. Dr. Chen also held research positions at TCW Pharmaceutical, Galileo Laboratories, Bristol-Myers Pharmaceutical and Yale University School of Medicine's Department of Pharmacology. Dr. Chen received his Ph.D. in Chemistry from Auburn University. He is the author of more than 60 scientific publications and a member of the editorial boards of Antiviral Chemistry and Chemotherapy and Biochemical Pharmacology and has served on several National Institutes of Health study sections.
James A.D. Smith, President and Chief Executive Officer said, ``Genelabs is in an exciting period of our history. In May we began submission of a New Drug Application (NDA) for United States marketing approval of GL701, our investigational drug for treatment of the chronic autoimmune disease systemic lupus erythematosus, and intend to complete submission by the end of 2000.''
``Our research is focused on using our proprietary technologies to discover a new class of pharmaceutical products that selectively regulate gene expression by binding to DNA. Ms. Hughes brings her many years of experience as a human resources professional to Genelabs. Her role on the management team is important as our company prepares for future growth.'' Mr. Smith continued, ``Dr. Chen's drug discovery experience is ideally suited to Genelabs' stage of development as we optimize our lead compounds to become drug candidates. We are pleased to have a scientist with his pharmaceutical discovery and development experience leading our research team.''
Separately, the company said that Richard A. Waldron, Vice President and Chief Financial Officer, is no longer employed by Genelabs. His responsibilities are being handled by Matthew M. Loar, Vice President of Finance, and Mr. Smith.
Genelabs Technologies, Inc. is a biopharmaceutical company engaged in the discovery and development of a new class of pharmaceutical products that selectively regulate gene expression or inactivate pathogens by binding directly to DNA or RNA, the fundamental material of genes. By acting directly on the genetic material, Genelabs' technology can be applicable to a wide range of therapeutic applications including diseases such as cancer and autoimmune disorders and infectious diseases caused by bacteria and viruses. The company has a near-term product opportunity in GL701, which has completed two Phase III clinical trials for systemic lupus erythematosus. Genelabs is seeking US FDA approval of GL701 as a first line therapy for women with active SLE to stabilize or improve their disease signs and symptoms, and also for SLE patients who are corticosteroid dependent, to reduce their corticosteroid dose.
NOTE: Except for historical information, the statements in this news release are forward-looking and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include, without limitation, whether FDA will approve GL701 for marketing in the United States and, if approved, the timing of such approval. The company has not submitted applications for regulatory review outside the US and its application in the US is not complete. Please see the information appearing in the company's filings with the Securities and Exchange Commission for more discussion regarding these uncertainties and risks and those associated with the company's research programs, early stage of development and other risks that may affect the company. The company does not undertake any obligation to update these forward-looking statements to reflect events or circumstances after the date of this release.
Genelabs' press releases are available by fax 24 hours a day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, extension 115419. They are also available on the Internet at genelabs.com and prnewswire.com .
CONTACT: James A. D. Smith, President and Chief Executive Officer of Genelabs Technologies, Inc., 650-562-1424.
SOURCE: Genelabs Technologies, Inc. |
